GlassScriptPhysician profile
Chere Lucas Anthony
NPI 1346456365
$13,750.08
in general payments reported to CMS, 2019-2025
42 companies · $4,312 in 2025
The $4,312 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $817 · 2021: $1,495 · 2022: $1,960 · 2023: $1,871 · 2024: $1,897 · 2025: $4,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133 · Travel and Lodging: $1,946.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.65 |
| Travel and Lodging | $1,946.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,480.38 | 2019-2025 | |
| Genzyme Corporation | $869.18 | 2019-2025 | |
| Incyte Corporation | $653.95 | 2021-2025 | Opzelura |
| Pfizer INC. | $607.86 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $546.82 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $534.22 | 2019-2025 | Winlevi, Absorica Ld, Blu-U |
| Galderma Laboratories, L.P. | $517.43 | 2019-2025 | Nemluvio, Dysport, Aklief |
| Regeneron Healthcare Solutions, INC. | $505.11 | 2019-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $370.80 | 2019-2021 | |
| Allergan, INC. | $367.77 | 2019-2022 | |
| Janssen Biotech, INC. | $362.94 | 2019-2023 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $346.38 | 2020-2024 | Otezla |
| Almirall LLC | $340.97 | 2019-2025 | Seysara, Klisyri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.56 | 2022-2025 | Spevigo |
| Ucb, INC. | $292.30 | 2019-2025 | Bimzelx |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $259.48 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $166.34 | 2022-2025 | Sotyktu |
| Vyne Pharmaceuticals INC. | $157.69 | 2020-2021 | |
| Dermavant Sciences, INC. | $148.32 | 2023-2024 | Vtama |
| Leo Pharma INC. | $135.38 | 2019-2025 | Spevigo, Anzupgo, Adbry |
| Mayne Pharma Commercial LLC | $115.92 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $92.84 | 2023-2025 | Zoryve |
| Nabriva Therapeutics, Plc | $78.74 | 2022 | |
| Prugen, INC. Pharmaceuticals | $75.22 | 2019 | |
| Ani Pharmaceuticals, INC. | $71.10 | 2025 | Veregen, Oxistat |
| Biofrontera INC. | $67.03 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Epi Health, LLC | $48.25 | 2020-2021 | |
| Musculoskeletal Transplant Foundation INC. | $38.51 | 2023 | |
| Celgene Corporation | $38.24 | 2019 | |
| Mylan Pharmaceuticals INC. | $37.69 | 2019 | |
| Pierre Fabre Pharmaceuticals, INC. | $23.71 | 2019-2020 | |
| Journey Medical Corporation | $19.39 | 2023 | |
| Dermira, INC. | $18.40 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $16.14 | 2022 | |
| Dusa Pharmaceuticals, INC. | $13.90 | 2019 | |
| Organon LLC | $8.12 | 2024 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chere Lucas Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.